ProShares UltraShort NASDAQ Biotechnology
10 hedge funds and large institutions have $6.05M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
9% less funds holding
Funds holding: 11 → 10 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Holders
10
Holding in Top 10
1
Calls
$247K
Puts
–
Top Buyers
| 1 | +$1.46M | |
| 2 | +$220K | |
| 3 | +$157K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$154K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$40.4K |
Top Sellers
| 1 | -$1.04M | |
| 2 | -$295K | |
| 3 | -$252K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$68K |
| 5 |
Citigroup
New York
|
-$1.94K |